The Complexities of Treating Rosacea, with Benjamin Ungar, MD
Benjamin Ungar, MD, explains the phenotypic and molecular manifestations of Rosacea, and the work still needed to develop targeted treatments.
Benjamin Ungar, MD, is a board-certified dermatologist at Mount Sinai, serving as the Director of the Alopecia Center of Excellence and the Rosacea & Seborrheic Dermatitis Clinic, and an Assistant Professor at the Icahn School of Medicine.
He joined Patient Care© Online editors live at the 2025 American Academy of Dermatology conference in Orlando to discuss his presentation, including discussion of the phenotypic and molecular manifestations of rosacea, and the need for more targeted treatments.
For more 2025 AAD Meeting coverage, please click here.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
